-
Je něco špatně v tomto záznamu ?
Avidity of anti-phospholipid antibodies in relation to their levels
L. FialovÁ, O. KuchaŘ, M. PetrÁČkovÁ, I. Malbohan, T. Zima
Jazyk angličtina Země Polsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2002
Free Medical Journals
od 2002
PubMed Central
od 2014
Europe PubMed Central
od 2014
ProQuest Central
od 2014-01-01 do 2022-04-30
Open Access Digital Library
od 2014-01-01
Nursing & Allied Health Database (ProQuest)
od 2014-01-01 do 2022-04-30
Health & Medicine (ProQuest)
od 2014-01-01 do 2022-04-30
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
33456323
DOI
10.5114/ceji.2020.97901
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Introduction: The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of their titres, from very low to high ones. Material and methods: We analyzed 78 serum samples from 60 patients by ELISA with chaotropic agents, using urea concentration of 6 and 8 mol/l and single diluted serum samples. The changes of aCL levels and avidities were explored during a long-term follow-up in 14 patients. Results: The avidities of aCLs did not differ in the groups of patients classified according to aCL levels. The higher avidity antibodies predominated in our patients and the fluctuation of avidities in the longitudinal follow-up did not show significant differences. No relationship between aCL levels and their avidities was found. Conclusions: aCL avidities seem to have no relationship with aCL levels and high-avidity aCLs; the potentially deleterious effects might be present also in patients with low and extremely low aCL levels. Avidity of aCLs belongs to stable characteristics with insignificant changes in time.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21010262
- 003
- CZ-PrNML
- 005
- 20210610095908.0
- 007
- ta
- 008
- 210413s2020 pl f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5114/ceji.2020.97901 $2 doi
- 035 __
- $a (PubMed)33456323
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a FialovÁ, Lenka $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 245 10
- $a Avidity of anti-phospholipid antibodies in relation to their levels / $c L. FialovÁ, O. KuchaŘ, M. PetrÁČkovÁ, I. Malbohan, T. Zima
- 520 9_
- $a Introduction: The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of their titres, from very low to high ones. Material and methods: We analyzed 78 serum samples from 60 patients by ELISA with chaotropic agents, using urea concentration of 6 and 8 mol/l and single diluted serum samples. The changes of aCL levels and avidities were explored during a long-term follow-up in 14 patients. Results: The avidities of aCLs did not differ in the groups of patients classified according to aCL levels. The higher avidity antibodies predominated in our patients and the fluctuation of avidities in the longitudinal follow-up did not show significant differences. No relationship between aCL levels and their avidities was found. Conclusions: aCL avidities seem to have no relationship with aCL levels and high-avidity aCLs; the potentially deleterious effects might be present also in patients with low and extremely low aCL levels. Avidity of aCLs belongs to stable characteristics with insignificant changes in time.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a KuchaŘ, Oliver $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a PetrÁČkovÁ, Milada $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Malbohan, Ivan $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Zima, TomÁŠ $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 773 0_
- $w MED00173245 $t Central-European journal of immunology $x 1426-3912 $g Roč. 45, č. 2 (2020), s. 136-143
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33456323 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210413 $b ABA008
- 991 __
- $a 20210610095907 $b ABA008
- 999 __
- $a ind $b bmc $g 1649754 $s 1130638
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 45 $c 2 $d 136-143 $e 20200727 $i 1426-3912 $m Central-European Journal of Immunology $n Cent.-Eur. J. Immunol. $x MED00173245
- LZP __
- $a Pubmed-20210413